The absence of human equilibrative nucleoside transporter 1 expression predicts nonresponse to gemcitabine-containing chemotherapy in non-small cell lung cancer

Cancer Letters

Volumn 256, Issue 1, 2007, Pages 112-119

  Oguri, Tetsuya ^a   Achiwa, Hiroyuki ^a   Muramatsu, Hideki ^a   Ozasa, Hiroaki ^a   Sato, Shigeki ^a   Shimizu, Shigeki ^a   Yamazaki, Hideko ^a   Eimoto, Tadaaki ^a   Ueda, Ryuzo ^a  

^a NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

Author keywords

Gemcitabine; hENT1; Immunohistochemistry; NSCLC

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; GEMCITABINE; NAVELBINE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER STAGING; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG MECHANISM; DRUG RESPONSE; DRUG SENSITIVITY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MALE; MONOTHERAPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR BIOPSY;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; CARCINOMA, LARGE CELL; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; DEOXYCYTIDINE; DRUG RESISTANCE, NEOPLASM; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 34548203759     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2007.06.012     Document Type: Article

References (22)

1. Schiller J.H., Harrington D., Belani C.P., Langer C., Sandler A., Krook J., et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N. Engl. J. Med. 346 (2002) 92-98
2. Huang P., Chubb S., Hertel L.W., Grindey G.B., and Plunkett W. Action of 2′,2-difluorodeoxycytidine on DNA synthesis. Cancer Res. 51 (1991) 6110-6117
3. Griffith D.A., and Jarvis S.M. Nucleoside and nucleobase transport systems of mammalian cells. Biochim. Biophys. Acta 1286 (1996) 153-181
4. Baldwin S.A., Mackey J.R., Cass C.E., and Young J.D. Nucleoside transporters: molecular biology and implications for therapeutic development. Mol. Med. Today 5 (1999) 216-224
5. Griffiths M., Beaumont N., Yao S.Y., Sundaram M., Boumah C.E., Davies A., et al. Cloning of a human nucleoside transporter implicated in the cellular uptake of adenosine and chemotherapeutic drugs. Nat. Med. 3 (1997) 89-93
6. Mackey J.R., Yao S.Y.M., Smith K.M., Karpinski E., Baldwin S.A., Cass C.E., et al. Gemcitabine transport in Xenopus oocytes expressing recombinant plasma membrane mammalian nucleoside transporters. J. Natl. Cancer. Inst. (Bethesda) 91 (1999) 1876-1881
7. Mackey J.R., Mani R.S., Selner M., Mowles D., Young J.D., Belt J.A., et al. Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines. Cancer Res. 58 (1998) 4349-4357
8. Garcia-Manteiga J., Molina-Arcas M., Casado F.J., Mazo A., and Pastor-Anglada M. Nucleoside transporter profiles in human pancreatic cancer cells: role of hCNT1 in 2',2'-difluorodeoxycytidine-induced cytotoxicity. Clin. Cancer Res. 9 (2003) 5000-5008
9. Pennycooke M., Chaudary N., Shuralyova I., Zhang Y., and Coe I.R. Differential expression of human nucleoside transporters in normal and tumor tissue. Biochem. Biophys. Res. Commun. 280 (2001) 951-959
10. Achiwa H., Oguri T., Sato S., Maeda H., Niimi T., and Ueda R. Determinants of sensitivity and resistance to gemcitabine: the roles of human equilibrative nucleoside transporter 1 and deoxycytidine kinase in non-small cell lung cancer. Cancer Sci. 95 (2004) 753-757
11. Ishii M., Iwahana M., Mitsui I., Minami M., Imagawa S., Tohgo A., et al. Growth inhibitory effect of a new camptothecin analog, DX-8951f, on various drug-resistant sub's including BCRP-mediated camptothecin derivative-resistant variants derived from the human lung cancer cell line PC-6. Anticancer Drugs 11 (2000) 353-362
12. Oguri T., Achiwa H., Bessho Y., Muramatsu H., Maeda H., Niimi T., et al. The role of thymidylate synthase and dihydropyrimidine dehydrogenase in resistance to 5-fluorouracil in human lung cancer cells. Lung Cancer 49 (2005) 345-351
13. Marce S., Mlina-Arcas M., Villamor N., Casado F.J., Campo E., Pastor-Anglada M., et al. Expression of human equilibrative nucleoside transporter 1 (hENT1) and its correlation with gemcitabine uptake and cytotoxicity in mantle cell lymphoma. Haematologica 91 (2006) 895-902
14. Giovannetti E., Del Tacca M., Mey V., Funel N., Nannizzi S., Ricci S., et al. Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine. Cancer Res. 66 (2006) 3928-3933
15. Goh L.B., Mack P., and Lee C.W. Nitrobenzylthioinosine-binding protein overexpression in human breast, liver, stomach and colorectal tumour tissues. Anticancer Res. 15 (1995) 2575-2579
16. Mackey J.R., Jennings L.L., Clarke M.L., Santos C.L., Dabbagh L., Vsianska M., et al. Immunohistochemical variation of human equilibrative nucleoside transporter 1 protein in primary breast cancers. Clin. Cancer Res. 8 (2002) 110-116
17. Dabbagh L., Coupland R.W., Cass C.E., and Mackey J.R. Immunohistochemical variation of human equilibrative nucleoside transporter 1 protein in primary breast cancers. Clin. Cancer Res. 9 (2003) 3213-3214
18. Farre X., Guillen-Gomez E., Sanchez L., Hardisson D., Plaza Y., Lloberas J., et al. Expression of the nucleoside-derived drug transporters hCNT1, hENT1 and hENT2 in gynecologic tumors. Int. J. Cancer 112 (2004) 959-966
19. Spratlin J., Sangha R., Glubrecht D., Dabbagh L., Young J.D., Dumontet C., et al. The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma. Clin. Cancer Res. 10 (2004) 6956-6961
20. Seve P., Mackey J.R., Isaac S., Tredan O., Souquet P.J., Perol M., et al. cN-II expression predicts survival in patients receiving gemcitabine for advanced non-small cell lung cancer. Lung Cancer 49 (2005) 363-370
21. Oguri T., Achiwa H., Sato S., Bessho Y., Takano Y., Miyazaki M., et al. The determinants of sensitivity and acquired resistance to gemcitabine differ in non-small cell lung cancer: a role of ABCC5 in gemcitabine sensitivity. Mol. Cancer Ther. 5 (2006) 1800-1806
22. Bepler G., Kusmartseva I., Sharma S., Gautam A., Cantor A., Sharma A., et al. RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer. J. Clin. Oncol. 24 (2006) 4731-4737